1. Ministry of Health and Welfare, Department of Central Cancer Registry. 2006-2007 cancer statistics. 2009. 1–34.
2. Goudas LC, Bloch R, Gialeli-Goudas M, Lau J, Carr DB. The epidemiology of cancer pain. Cancer Invest. 2005. 23:182–190.
Article
3. Meuser T, Pietruck C, Radbruch L, Stute P, Lehmann KA, Grond S. Symptoms during cancer pain treatment following WHO-guidelines: a longitudinal follow-up study of symptom prevalence, severity and etiology. Pain. 2001. 93:247–257.
Article
4. Benedetti C, Brock C, Cleeland C, Coyle N, Dubé JE, Ferrell B, et al. NCCN Practice Guidelines for Cancer Pain. Oncology (Williston Park). 2000. 14:135–150.
5. Zech DF, Grond S, Lynch J, Hertel D, Lehmann KA. Validation of World Health Organization Guidelines for cancer pain relief: a 10-year prospective study. Pain. 1995. 63:65–76.
Article
6. Samuelsson H, Malmberg F, Eriksson M, Hedner T. Outcomes of epidural morphine treatment in cancer pain: nine years of clinical experience. J Pain Symptom Manage. 1995. 10:105–112.
Article
7. Smitt PS, Tsafka A, Teng-van de Zande F, van der Holt R, Elswijk-de Vries I, Elfrink E, et al. Outcome and complications of epidural analgesia in patients with chronic cancer pain. Cancer. 1998. 83:2015–2022.
Article
8. Samuelsson H, Hedner T. Pain characterization in cancer patients and the analgetic response to epidural morphine. Pain. 1991. 46:3–8.
Article
9. Du Pen SL, Kharasch ED, Williams A, Peterson DG, Sloan DC, Hasche-Klunder H, et al. Chronic epidural bupivacaine-opioid infusion in intractable cancer pain. Pain. 1992. 49:293–300.
Article
10. Ballantyne JC, Carwood CM. Comparative efficacy of epidural, subarachnoid, and intracerebroventricular opioids in patients with pain due to cancer. Cochrane Database Syst Rev. 2005. CD005178.
Article
11. Bedder MD, Burchiel K, Larson A. Cost analysis of two implantable narcotic delivery systems. J Pain Symptom Manage. 1991. 6:368–373.
Article
12. Erdine S, Aldemir T. Long-term results of peridural morphine in 225 patients. Pain. 1991. 45:155–159.
Article
13. Burton AW, Rajagopal A, Shah HN, Mendoza T, Cleeland C, Hassenbusch SJ 3rd, et al. Epidural and intrathecal analgesia is effective in treating refractory cancer pain. Pain Med. 2004. 5:239–247.
Article
14. Mercadante S. Controversies over spinal treatment in advanced cancer patients. Support Care Cancer. 1998. 6:495–502.
Article
15. Jeon YS, Kim HK, Cleeland CS, Wang XS. Clinicians' practice and attitudes toward cancer pain management in Korea. Support Care Cancer. 2007. 15:463–469.
Article
16. Hong SH, Roh SY, Kim SY, Shin SW, Kim CS, Choi JH, et al. Change in cancer pain management in Korea between 2001 and 2006: results of two nationwide surveys. J Pain Symptom Manage. 2011. 41:93–103.
Article
17. Sjöberg M, Karlsson PA, Nordborg C, Wallgren A, Nitescu P, Appelgren L, et al. Neuropathologic findings after long-term intrathecal infusion of morphine and bupivacaine for pain treatment in cancer patients. Anesthesiology. 1992. 76:173–186.
Article
18. Congedo E, Sgreccia M, De Cosmo G. New drugs for epidural analgesia. Curr Drug Targets. 2009. 10:696–706.
Article
19. Ruppen W, Derry S, McQuay HJ, Moore RA. Infection rates associated with epidural indwelling catheters for seven days or longer: systematic review and meta-analysis. BMC Palliat Care. 2007. 6:3.
Article
20. Hogan Q, Haddox JD, Abram S, Weissman D, Taylor ML, Janjan N. Epidural opiates and local anesthetics for the management of cancer pain. Pain. 1991. 46:271–279.
Article
21. Hogan QH. Loculated? Encapsulated? Indented? Pain. 1993. 53:241–242.
Article
22. Chamberlain BH, Cross K, Winston JL, Thomas J, Wang W, Su C, et al. Methylnaltrexone treatment of opioid-induced constipation in patients with advanced illness. J Pain Symptom Manage. 2009. 38:683–690.
Article
23. Mercadante S, Agnello A, Armata MG, Pumo S. The inappropriate use of the epidural route in cancer pain. J Pain Symptom Manage. 1997. 13:233–237.
Article